Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MOREFor the prevention of early mortality in day-old chickens associated with Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa
LEARN MORETreatment for subclinical infectious bovine mastitis in lactating cows due to Streptococcus agalactiae and penicillin-sensitive Staphylococcus aureus.
LEARN MORE